Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | phosphodiesterase 10A | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Brugia malayi | Probable 3',5'-cyclic phosphodiesterase C32E12.2, putative | Get druggable targets OG5_135363 | All targets in OG5_135363 |
Echinococcus granulosus | cAMP and cAMP inhibited cGMP 3'5' cyclic | Get druggable targets OG5_135363 | All targets in OG5_135363 |
Loa Loa (eye worm) | hypothetical protein | Get druggable targets OG5_135363 | All targets in OG5_135363 |
Loa Loa (eye worm) | hypothetical protein | Get druggable targets OG5_135363 | All targets in OG5_135363 |
Echinococcus multilocularis | cAMP and cAMP inhibited cGMP 3',5' cyclic | Get druggable targets OG5_135363 | All targets in OG5_135363 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma brucei | cAMP-specific phosphodiesterase | phosphodiesterase 10A | 789 aa | 666 aa | 30.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | peptidyl glycine alpha amidating monooxygenase | 0.0692 | 1 | 1 |
Brugia malayi | Copper type II ascorbate-dependent monooxygenase, C-terminal domain containing protein | 0.0367 | 0.365 | 0.365 |
Loa Loa (eye worm) | hypothetical protein | 0.0692 | 1 | 1 |
Echinococcus granulosus | peptidyl glycine alpha amidating monooxygenase | 0.0692 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0367 | 0.365 | 0.255 |
Brugia malayi | Probable 3',5'-cyclic phosphodiesterase C32E12.2, putative | 0.0289 | 0.2113 | 0.2113 |
Brugia malayi | Copper type II ascorbate-dependent monooxygenase, N-terminal domain containing protein | 0.0186 | 0.0107 | 0.0107 |
Loa Loa (eye worm) | hypothetical protein | 0.028 | 0.1936 | 0.0539 |
Schistosoma mansoni | peptidyl-glycine monooxygenase | 0.0692 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 8.4 nM | BindingDB_Patents: Inhibition Assay. A PDE10A assay may for example, be performed as follows: The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide substrate); a buffer (50 mM HEPES7.6; 10 mM MgCl2; 0.02% Tween20), 0.1 mg/ml BSA, 225 pCi of 3H-labelled cyclic nucleotide substrate, tritium labeled cAMP to a final concentration of 5 nM and varying amounts of inhibitors. Reactions are initiated by addition of the cyclic nucleotide substrate, and reactions are allowed to proceed for one hr at room temperature before being terminated through mixing with 15 uL 8 mg/mL yttrium silicate SPA beads (Amersham). The beads are allowed to settle for one hr in the dark before the plates are counted in a Wallac 1450 Microbeta counter. | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.